Results 11 to 20 of about 1,126 (138)

Emicizumab-induced photosensitivity

TH Open, 2022
AbstractEmicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression. To the best of our knowledge, this side effect had not been communicated until present.
Pedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, Jürgen Solís Ruiz, Ana Rosa Cid Haro, Santiago Bonanad Boix, Saturnino Haya Guaita   +6 more
openaire   +4 more sources

Emicizumab Associated Rhabdomyolysis in Hemophilia A [PDF]

Clinical Hematology International, 2020
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present.
Joseph A. Wilson, Stephanie Hayden, Alexander Asamoah, Vivek R. Sharma, David C. Jennings, Ashok B. Raj   +5 more
openaire   +5 more sources

Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab has emerged as a promising therapy for hemophilia A (HA), employing a bypassing mechanism to restore hemostasis. However, since the traditional factor assays cannot be used for measuring the effect of emicizumab, treatment ...
Charlotte Gran MD, PhD, Tony Frisk MD, PhD, Margareta Homström MD, PhD, Maria Magnusson MD, PhD, Susanna Ranta MD, PhD, Anna Sjöström MD, PhD, Marjan Shafaati Lambert, Nida Mahmoud Hourani Soutari BSc, Jovan P. Antovic MD, PhD, Roza Chaireti MD, PhD   +9 more
doaj   +2 more sources

Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry

Blood Advances
: Emicizumab prophylaxis has been approved in Canada for the prevention or reduction of bleeding episodes in people with congenital hemophilia A (PwHA).
Alfonso Iorio, Federico Germini, Quazi Ibrahim, Arun Keepanasseril, Davide Matino, Emma Iserman, Adrienne Lee, Letizia Polito, Katya Moreno, Michelle Santos, Man-Chiu Poon   +10 more
doaj   +2 more sources

Anti-emicizumab antibodies and their relevance in clinical practice

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is licensed for treatment of people with hemophilia A (HA) of all ages, with and without factor (F)VIII inhibitors. It is well tolerated, and most of the treatment-related adverse events are of mild intensity and transient.
Carla Valsecchi, Lucia Schiavone, Sara Arcudi, Adriana Torri, Cristina Novembrino, Flora Peyvandi   +5 more
doaj   +2 more sources

Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab, a bispecific factor VIII mimetic antibody, was approved in 2018 for bleeding prophylaxis in congenital hemophilia A with or without inhibitors.
Ghachem Ikbel MD, Baccouche Hela MD, Kaabar Mohamed Yassine MD, Khemiri Hamida MD, Ben Salem Kamel MD   +4 more
doaj   +2 more sources

Importance of Inhibitor Surveillance During Emicizumab Prophylaxis in Young Children With Hemophilia: An Illustrative Case Series

Case Reports in Hematology
Hemophilia is an X-linked inherited bleeding disorder associated with bleeding, which starts in infancy. The age of initiation of prophylaxis with clotting factor concentrate is limited by the intravenous mode of administration. Emicizumab, a Factor VIII
Kelly A. Bush, Marc Durocher, Jacqueline Limjoco, Courtney D. Thornburg   +3 more
doaj   +2 more sources

Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors’ Organisation [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab prophylaxis is restricted to severe hemophilia A in the UK. Treatment choice and safety remain a matter of debate. Objectives: This study was conducted to investigate factors influencing treatment choice, continued use, safety, and
Caroline Wall, Hua Xiang, Ben Palmer, Pratima Chowdary, Peter W. Collins, Richard Gorman, Mary Matthias, Charles Percy, Paul Sartain, Susan Shapiro, David Stephensen, Kate Talks, Charles R.M. Hay   +12 more
doaj   +2 more sources

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed.
Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Sara Arcudi, Roberta Gualtierotti, Cristina Novembrino, Flora Peyvandi   +6 more
doaj   +2 more sources

Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres [PDF]

, 2023
INTRODUCTION Haemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres.
Jan Blatny, Ranta, Susanna, Nadine G. Andersson, Kathelijn Fischer, Martina Bührlen, Christoph Male, Escuriola, Carmen, Gili Kenet, d'Oiron, Roseline, Ester Zapotocka, Blatny, Jan, Kenet, Gili, Motwani, Jayashree, Königs, Christoph, Mutlu Kartal‐Kaess, Andersson, Nadine G., Carcao, Manuel, Marloes de Kovel, Roseline d'Oiron, de Kovel, Marloes, Kartal-Kaess, Mutlu, Andersson, Nadine, Martin Olivieri, Carmen Escuriola, Zapotocka, Ester, Jayashree Motwani, Male, Christoph, Christoph Königs, Manuel Carcao, Susanna Ranta, Bührlen, Martina, Andersson, Nadine G, Nolan, Beatrice, Olivieri, Martin, Chambost, Hervé, Fischer, Kathelijn, Beatrice Nolan, Hervé Chambost, Chambost, H, Male, Christoph,, Buehrlen, M, Fischer, Kathelijn,, Kartal-Kaess, Mutlu,, Blatny, Jan,, Andersson, Nadine G.,, Bührlen, Martina,, Zapotocka, Ester,, Carcao, M, Blatny, J, Lund University., d'Oiron, Roseline,, Kartal-Kaess, M, Königs, Christoph,, Olivieri, Martin,, Fischer, K, Ranta, S,, Motwani, J, Escuriola, C, Motwani, Jayashree,, Carcao, Manuel,, Ranta, Susanna,, Nolan, Beatrice,, de, Kovel M, de Kovel, Marloes,, Kenet, Gili,, Escuriola, Carmen,, Chambost, Hervé,   +66 more
core   +5 more sources